Decision points for the initiation of systemic treatment for psoriasis
- 31 July 2005
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 53 (1), 101-107
- https://doi.org/10.1016/j.jaad.2005.03.050
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- AAD consensus statement on psoriasis therapiesJournal of the American Academy of Dermatology, 2003
- The Development of a Disease-Specific Questionnaire to Assess Quality of Life for Psoriasis Patients: An Analysis of the Reliability, Validity, and Responsiveness of the Psoriasis Quality of Life QuestionnaireDermatology and Psychosomatics / Dermatologie und Psychosomatik, 2002
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- The Physical, Psychological and Social Impact of PsoriasisJournal of Health Psychology, 1997
- Skindex, a Quality-of-Life Measure for Patients with Skin Disease: Reliability, Validity, and ResponsivenessJournal of Investigative Dermatology, 1996
- 6-Thioguanine treatment of psoriasis: Experience in 81 patientsJournal of the American Academy of Dermatology, 1994
- Hydroxyurea therapyJournal of the American Academy of Dermatology, 1991
- Risk of Cutaneous Carcinoma in Patients Treated with Oral Methoxsalen Photochemotherapy for PsoriasisNew England Journal of Medicine, 1979